<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151339">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893489</url>
  </required_header>
  <id_info>
    <org_study_id>Ga_MSA_CAD_carotid</org_study_id>
    <nct_id>NCT01893489</nct_id>
  </id_info>
  <brief_title>Visualization of Carotid Atherosclerosis by 68Ga-MSA</brief_title>
  <official_title>Phase I Study to Evaluated the Safety of Noninvasive Molecular Imaging for the Detection of Inflammation in Carotid Atherosclerotic Lesions by Using Ga-68-NOTA-MSA in Healthy Volunteers and Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SHIN JIN MEDICS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Korea University</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Until now, no specific atherosclerosis-targeting agent labeled with positron emitter is not
      yet available. Investigators developed neomannosyl human serum albumin(MSA) for the terminal
      mannose residues of MSA binding with the mannose receptors of macrophages in
      atherosclerosis, and investigators investigate whether 68Ga-MSA can be a novel agent for
      non-invasive molecular imaging of carotid atherosclerotic lesion in PET.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>side reactions at MSA injection site of the skin</measure>
    <time_frame>with 2 hours after MSA injection</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>development of unexpected skin rashes or other skin lesions at  MSA injection site of the skin with 2 hours after MSA injection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>unstable changes of vital signs and development of abnormal biochemical parameters</measure>
    <time_frame>24 hours after MSA injection</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This includes unstable changes of vital signs including blood pressure, body temperature and heart rate, and abnormal changes of biochemical parameters such as hematologic, hepatic and renal functions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>standard uptake unit(SUV) at carotid arteries</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUV at aorta and iliac arteries</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Carotid Atherosclerosis</condition>
  <condition>Noninvasive Imaging of Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Atherosclerosis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>coronary artery disease patients with carotid plaques confirmed by a ultrasound study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>no coronary artery disease patients without carotid plaques confirmed by a ultrasound study</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>68Gallium-MSA</intervention_name>
    <description>68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging</description>
    <arm_group_label>Atherosclerosis</arm_group_label>
    <arm_group_label>control</arm_group_label>
    <other_name>68Gallium-MSA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  •coronary artery disease patients with carotid plaques

               -  control without carotid plaque

        Exclusion Criteria:

          -  •pregnancy, allergy to albumin, any acute or chronic inflammatory disease,
             hematologic disease, liver disease, renal disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Institute of Radiation Medicine,</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 23, 2013</lastchanged_date>
  <firstreceived_date>June 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Korea University</investigator_affiliation>
    <investigator_full_name>Hong Seog Seo</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>positron emission tomography</keyword>
  <keyword>macrophage</keyword>
  <keyword>neomannosyl human serum albumin</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Carotid Artery Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
